Zuhaa Hassan Kazmi

Blinatumomab versus chemotherapy in pediatric B-ALL: A meta-analysis of randomized trials in relapsed and high-risk frontline disease

BACKGROUND: B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric cancer, comprising almost 25 % of childhood malignancies. Despite advances in chemotherapy, relapse remains a major cause of treatment failure, particularly in high-risk patients. Blinatumomab, a...